MX2019003748A - Polimorfos cristalinos de un agonista del receptor muscarinico de acetilcolina. - Google Patents
Polimorfos cristalinos de un agonista del receptor muscarinico de acetilcolina.Info
- Publication number
- MX2019003748A MX2019003748A MX2019003748A MX2019003748A MX2019003748A MX 2019003748 A MX2019003748 A MX 2019003748A MX 2019003748 A MX2019003748 A MX 2019003748A MX 2019003748 A MX2019003748 A MX 2019003748A MX 2019003748 A MX2019003748 A MX 2019003748A
- Authority
- MX
- Mexico
- Prior art keywords
- acetylcholine receptor
- muscarinic acetylcholine
- crystalline polymorphs
- receptor agonist
- methods
- Prior art date
Links
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title abstract 3
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title abstract 3
- 229940122578 Acetylcholine receptor agonist Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- PHOZOHFUXHPOCK-QMMMGPOBSA-N (2s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro[4.5]decan-3-one Chemical compound N1C(=O)[C@H](CC)SC11CCN(C)CC1 PHOZOHFUXHPOCK-QMMMGPOBSA-N 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003413 spiro compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
Abstract
Se proporcionan formas cristalinas novedosas de un compuesto espiro que actúa como un agonista del receptor muscarínico de acetilcolina. En particular, se describen polimorfos cristalinos aislados de (S)-2-etil-8-metil-1-tia-4,8-diazaespiro[4.5]decano-3- ona que tienen propiedades favorables en la preparación farmacéutica. También se proporcionan métodos para preparar dichos polimorfos cristalinos y para convertirlos entre sí, así como métodos para preparar medicamentos que contienen los mismos que son adecuados para usarse en el tratamiento de enfermedades y trastornos que responden a la modulación del receptor muscarínico de acetilcolina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16192494 | 2016-10-05 | ||
| PCT/EP2017/075373 WO2018065529A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline polymorphs of a muscarinic acetylcholine receptor agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019003748A true MX2019003748A (es) | 2019-08-12 |
| MX383581B MX383581B (es) | 2025-03-14 |
Family
ID=57083221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003748A MX383581B (es) | 2016-10-05 | 2017-10-05 | Polimorfos cristalinos de un agonista del receptor muscarinico de acetilcolina. |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US11008342B2 (es) |
| EP (1) | EP3523310B1 (es) |
| JP (3) | JP7163280B2 (es) |
| KR (1) | KR102710640B1 (es) |
| CN (1) | CN109790180A (es) |
| AU (1) | AU2017341088B2 (es) |
| CA (1) | CA3036134A1 (es) |
| CL (1) | CL2019000532A1 (es) |
| CO (1) | CO2019003003A2 (es) |
| CY (1) | CY1125464T1 (es) |
| DK (1) | DK3523310T3 (es) |
| EA (1) | EA201990376A1 (es) |
| ES (1) | ES2924432T3 (es) |
| HR (1) | HRP20220962T1 (es) |
| HU (1) | HUE059720T2 (es) |
| IL (2) | IL265747B2 (es) |
| LT (1) | LT3523310T (es) |
| MA (1) | MA46464B1 (es) |
| MD (1) | MD3523310T2 (es) |
| MX (1) | MX383581B (es) |
| PE (2) | PE20250745A1 (es) |
| PH (1) | PH12019550048B1 (es) |
| PL (1) | PL3523310T3 (es) |
| PT (1) | PT3523310T (es) |
| RS (1) | RS63438B1 (es) |
| SG (1) | SG11201901612TA (es) |
| SI (1) | SI3523310T1 (es) |
| SM (1) | SMT202200331T1 (es) |
| WO (1) | WO2018065529A1 (es) |
| ZA (1) | ZA201901695B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46464B1 (fr) | 2016-10-05 | 2022-10-31 | Nsc Therapeutics Gmbh | Polymorphes de l'agoniste de récepteur muscarinique |
| US12201619B2 (en) | 2018-03-22 | 2025-01-21 | Nsc Therapeutics Gmbh | Compounds and methods for use in the treatment of microglia-mediated disorders |
| AU2021376267A1 (en) * | 2020-11-03 | 2023-06-15 | Cassava Sciences, Inc. | Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855290A (en) | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| US6797558B2 (en) | 2001-04-24 | 2004-09-28 | Micron Technology, Inc. | Methods of forming a capacitor with substantially selective deposite of polysilicon on a substantially crystalline capacitor dielectric layer |
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| KR101027570B1 (ko) * | 2002-05-03 | 2011-04-06 | 이스라엘 인스티튜트 포 바이올로지컬 리서치 | 중추 및 말초 신경계 장애의 치료를 위한 방법 및 조성물, 및 그에 유용한 신규 화합물 |
| MA46464B1 (fr) | 2016-10-05 | 2022-10-31 | Nsc Therapeutics Gmbh | Polymorphes de l'agoniste de récepteur muscarinique |
| US12201619B2 (en) | 2018-03-22 | 2025-01-21 | Nsc Therapeutics Gmbh | Compounds and methods for use in the treatment of microglia-mediated disorders |
-
2017
- 2017-10-05 MA MA46464A patent/MA46464B1/fr unknown
- 2017-10-05 US US16/338,930 patent/US11008342B2/en active Active
- 2017-10-05 IL IL265747A patent/IL265747B2/en unknown
- 2017-10-05 MD MDE20190908T patent/MD3523310T2/ro unknown
- 2017-10-05 JP JP2019512714A patent/JP7163280B2/ja active Active
- 2017-10-05 MX MX2019003748A patent/MX383581B/es unknown
- 2017-10-05 PL PL17788131.5T patent/PL3523310T3/pl unknown
- 2017-10-05 SG SG11201901612TA patent/SG11201901612TA/en unknown
- 2017-10-05 HR HRP20220962TT patent/HRP20220962T1/hr unknown
- 2017-10-05 PE PE2024002026A patent/PE20250745A1/es unknown
- 2017-10-05 HU HUE17788131A patent/HUE059720T2/hu unknown
- 2017-10-05 DK DK17788131.5T patent/DK3523310T3/da active
- 2017-10-05 SI SI201731206T patent/SI3523310T1/sl unknown
- 2017-10-05 EA EA201990376A patent/EA201990376A1/ru unknown
- 2017-10-05 RS RS20220724A patent/RS63438B1/sr unknown
- 2017-10-05 PT PT177881315T patent/PT3523310T/pt unknown
- 2017-10-05 WO PCT/EP2017/075373 patent/WO2018065529A1/en not_active Ceased
- 2017-10-05 EP EP17788131.5A patent/EP3523310B1/en active Active
- 2017-10-05 KR KR1020197010921A patent/KR102710640B1/ko active Active
- 2017-10-05 CA CA3036134A patent/CA3036134A1/en active Pending
- 2017-10-05 PE PE2019000719A patent/PE20191003A1/es unknown
- 2017-10-05 PH PH1/2019/550048A patent/PH12019550048B1/en unknown
- 2017-10-05 LT LTEPPCT/EP2017/075373T patent/LT3523310T/lt unknown
- 2017-10-05 SM SM20220331T patent/SMT202200331T1/it unknown
- 2017-10-05 AU AU2017341088A patent/AU2017341088B2/en active Active
- 2017-10-05 CN CN201780060800.4A patent/CN109790180A/zh active Pending
- 2017-10-05 ES ES17788131T patent/ES2924432T3/es active Active
-
2019
- 2019-02-28 CL CL2019000532A patent/CL2019000532A1/es unknown
- 2019-03-19 ZA ZA2019/01695A patent/ZA201901695B/en unknown
- 2019-03-28 CO CONC2019/0003003A patent/CO2019003003A2/es unknown
-
2020
- 2020-12-22 US US17/130,564 patent/US11866449B2/en active Active
-
2022
- 2022-05-18 JP JP2022081233A patent/JP2022119840A/ja active Pending
- 2022-08-04 CY CY20221100533T patent/CY1125464T1/el unknown
-
2023
- 2023-06-28 IL IL304126A patent/IL304126A/en unknown
- 2023-11-21 US US18/516,585 patent/US20240083914A1/en active Pending
-
2024
- 2024-01-24 JP JP2024008595A patent/JP2024056724A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001983A1 (es) | Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4 | |
| CL2014001752A1 (es) | Compuestos biciclicos sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como cancer, alzheimer, sida, entre otras. | |
| CL2017000814A1 (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| CL2019000245A1 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos. | |
| CO2019004945A2 (es) | Inhibidores de la magl | |
| MX2017009841A (es) | 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, analogos y sales del mismo y su uso en terapia. | |
| CL2008001335A1 (es) | Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras. | |
| GT201400222A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
| MX2016012103A (es) | Agonistas del receptor muscarinico. | |
| PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
| MX376113B (es) | Derivados de azabenzimidazoles como moduladores del receptor ampa, y el uso de los mismos en el tratamiento de enfermedades asociadas con los receptores ampa. | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| CL2016002245A1 (es) | Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| PH12016502307A1 (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
| MX2016010328A (es) | Tratamiento con halogeno de ataque cardiaco y lesion isquemica. | |
| DOP2020000072A (es) | Amidas de imidazopiridina sustituidas y su uso | |
| CY1125464T1 (el) | Κρυσταλλικες πολυμορφικες ουσιες ενος ανταγωνιστη μουσκαρινικου υποδοχεα ακετυλοχολινης | |
| CL2018000856A1 (es) | Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida. | |
| MX2019010993A (es) | Derivados de tetrahidroquinolina como antagonistas del receptor p2x7. | |
| CL2016001024A1 (es) | Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades. | |
| CO2018011797A2 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| HK1235774A1 (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |